drugset / Trial / NCT06178601
A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2
Unknown
36 enrolled
Shanxi Province Cancer Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of RC48-ADC combined with AK104 in HER2-expression locally advanced or metastatic urothelial carcinoma.
Timeline
- Start
- 2023-08-03
- Primary completion
- 2024-09-01
- Completion
- 2026-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |